The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis

Annals of the New York Academy of Sciences

Volumn 1051, Issue , 2005, Pages 442-454

  Kobayashi, Kazuko ^a   Lopez, Luis R ^b   Shoenfeld, Yehuda ^c   Matsuura, Eiji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Division of Medicine   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antiphospholipid syndrome; Oxidized low density lipoprotein; 2 glycoprotein I

Indexed keywords

7 KETOCHOLESTERYL 9 CARBOXYNONANOATE; ANTIGEN; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CHOLESTEROL DERIVATIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGENICITY; ANTIPHOSPHOLIPID SYNDROME; ARTERY WALL; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; COMPLEX FORMATION; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALIA;

EID: 25444445803     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1361.086     Document Type: Conference Paper

References (69)

1. STEINBRECHER, U.P., S. PARTHASARATHY, D.S. LEAKE, et al. 1984. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA 81: 3883-3887.
2. STEINBERG, D., S. PARTHASARATHY, T.E. CAREW, et al. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924.
3. STEINBERG, D. 1997. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272: 20963-20966.
4. HAMMER, A., G. ICAGER, G. DOHR, et al. 1995. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15: 704-713.
5. PALINSKI, W., V.A. ORD, A.S. PLUMP, et al. 1994. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14: 605-616.
6. SALONEN, J.T., S. YLA-HERTTUALA, R. YAMAMOTO, et al. 1992. Autoantibody against oxidis ed LDL and progression of carotid atherosclerosis. Lancet 339: 883-887.
7. PALINSKI, W., E. MILLER & J.L. WITZTUM. 1995. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA 92: 821-825.
8. MCNEIL, H.P., R.J. SIMPSON, C.N. CHESTERMAN & S.A. KRILIS. 1990. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA 87: 4120-4124.
9. GALLI, M., P. COMFURIUS, C. MAASSEN, et al. 1990. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335: 1544-1547.
10. MATSUURA, E., Y. IGARASHI, M. FUJIMOTO, et al. 1990. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336: 177-178.
11. MATSUURA, E., Y. IGARASHI , M. FUJIMOTO, et al. 1992. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J. Immunol. 148: 3885-3891.
12. MATSUURA, E., Y. IGARASHI, T. YASUDA, et al. 1994. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 179: 457-462.
13. GEORGE, J., D. HARATS, B. GILBURD, et al. 1999. Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99: 2227-2230.
14. VAARALA, O., G. ALFTHAN, M. JAUHIAINEN, et al. 1993. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341: 923-925.
15. TINAHONES, F.J., M.J. CUADRADO, M.A. KHAMASHTA, et al. 1998. Lack of cross-reaction between antibodies to β2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome. Br. J. Rheumatol. 37: 746-749.
16. ROMERO, F.I., O. AMENGUAL, T. ATSUMI, et al. 1998. Arterial disease in lupus and secondary antiphospholipid syndrome: a ssociation with anti-β2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br. J. Rheumatol. 37: 883-888.
17. KOBAYASHI, K., M. KISHI, T. ATSUMI, et al. 2003. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J. Lipid Res. 44:716-726.
18. HASUNUMA, Y., E. MATSUURA, Z. MAKITA, et al. 1997. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol. 107: 569-573.
19. KOBAYASHI, K., E. MATSUURA, Q. LIU. et al. 2001. A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J. Lipid Res. 42: 697-709.
20. LIU, Q., K. KOBAYASHI, J. INAGAKI, et al. 2002. ω-carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J. Lipid Res. 43: 1486-1495.
21. STEINBERG, D. 2002. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. 8: 1211-1217.
22. VIRELLA, G., D.H. ATCHLEY, S. KOSKINEN, et al. 2002. Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin. Immunol. 105: 81-92.
23. BERLINER, J.A. & J.W. HEINECKE. 1996. The role of oxidized lipoproteins in atherogenesis. Free Radical Biol. & Med. 20: 707-727.
24. MCMURRAY, H.F., S. PARTHASARATHY & D. STEINBERG. 1993. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J. Clin. Invest. 92: 1004-1008.
25. YLA-HERTTUALA, S., W. PALINSKI, M.E. ROSENFELD, et al. 1989. Evidence for presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 85: 1086-1095.
26. VAARALA, O. 1996. Antiphospholipid antibodies and atherosclerosis. Lupus 5: 442-447.
27. PALINSKI, W., S. HORKKO, E. MILLER, et al. 1996. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98:800-814.
28. SHAW P.X., S. HORKKO, M.K. CHANG, et al. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105: 1731-1740.
29. HORKKO, S., N.A. BIRD, E. MILLER, et al. 1999. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103: 117-128.
30. ZHOU, X., G. CALIGIURI, A. HAMSTEN, et al. 2001. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21: 108-114.
31. CALIGIURI, G., A. NICOLETTI, B. POIRIER & G.K. HANSSON. 2002. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 109: 745-753.
32. GEORGE, J., A. AFEK, B. GILBURD, et al. 1998. Hyperimmunization of apo-E deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138: 147-152.
33. SHOENFELD, Y., D. HARATS & J. GEORGE. 2000. Heat shock protein 60/50, beta 2-glycoprotein I and oxidized LDL as players in murine atherosclerosis. J. Autoimmun. 15: 199-202.
34. CALIGIURI, G., M. RUDLING, V. OLLIVIER, et al. 2003. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol. Med. 9: 10-17.
35. IUGHETTI, L., C. VOLTA, E. MAGGI, et al. 1999. Circulating antibodies recognizing oxidatively modified low-density lipoprotein in children. Pediatr. Res. 45: 94-99.
36. VIRELLA, G., I. VIRELLA, R.B. LEMAN, et al. 1993. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int. J. Clin. Lab. Res. 23: 95-101.
37. WU, R., U. DE FAIRE, C. LEMNE, et al. 1999. Autoantibodies to oxLDL are decreased in individuals with borderline hypertension. Hypertension 33: 53-59.
38. LOPES-VIRELLA, M.F., G. VIRELLA, T.J. ORCHARD, et al. 1999. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin. Immunol. 90: 165-172.
39. SHOJI, T., Y. NISHIZAWA, M. FUKUMOTO, et al. 2000. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 148: 171-177.
40. FUKUMOTO, M., T. SHOJI, M. EMOTO, et al. 2000. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler. Thromb. Vasc. Biol. 20: 703-707.
41. FROSTEGARD, J., R. WU, C. LEMNE, et al. 2003. Circulating oxidized low-density lipoprotein is increased in hypertension. Clin. Sci. 105: 615-620.
42. YLA-HERTTUALA, S., W. PALINSKI, S.W. BUTLER, et al. 1994. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 14: 32-40.
43. WU, R., S. NITYANAND, L. BERGLUND, et al. 1997. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 17: 3159-3163.
44. PUURUNEN, M., M. MANTTARI, V. MANNINEN, et al. 1994. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch. Intern. Med. 154: 2605-2609.
45. GEORGE, J., A. AHMED, M. PATNAIK, et al. 2000. The prediction of coronary atherosclerosis employing artificial neural networks. Clin. Cardiol. 23: 453-456.
46. George, J., D. Harats, E. Bakshi, et al. 1999. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol. Lett. 68: 263-266.
47. BERGMARK, C., R. WU, U. DE FAIRE, et al. 1995. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 15: 441-445.
48. LIBBY, P. 2002. Inflammation in atherosclerosis. Nature 420: 868-874.
49. WU, R. & A.K. LEFVERT. 1995. Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotope, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin. Exp. Immunol. 102: 174-180.
50. VIRELLA, G., D. ATCHLEY, S. KOSKINEN, et al. 2002. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin. Immunol. 105: 81-92.
51. MIRONOVA, M., G. VIRELLA & M.F. LOPES-VIRELLA. 1996. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler. Thromb. Vasc. Biol. 16: 222-229.
52. WU, R., Y. SHOENFELD, Y. SHERER, et al. 2003. Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations-possible immunomodulation of atherosclerosis. Autoimmunity 36: 91-97.
53. DEVEY, M.E. & D. VOAK. 1974. A critical study of the IgG subclasses of Rh anti-D antibodies formed in pregnancy and in immunized volunteers. Immunology 27: 1073-1079.
54. HENRIKSEN, T., E.M. MAHONEY & D. STEINBERG. 1981. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc. Natl. Acad. Sci USA 78: 6499-6503.
55. WU, R., E. SVENUNGSSON, I. GUNNARSSON, et al. 1999. Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus. Clin. Exp. Immunol. 115: 561-566.
56. ZHAO, D., H. OGAWA, X. WANG, et al. 2001. Oxidized low-density lipoprotein and autoimmune antibodies in patients with antiphospholipid syndrome with a history of thrombosis. Am. J. Clin. Pathol. 116: 760-767.
57. CVETKOVIC, J.T., S. WALLBERG-JONSSON, E. AHMED, et al. 2002. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology (Oxford) 41: 988-995.
58. WU, R., E. SVENUNGSSON, I. GUNNARSSON, et al. 1999. Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE. Lupus 8: 142-150.
59. WU, R., E. SVENUNGSSON, I. GUNNARSSON, et al. 1999. Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus. Clin. Exp. Immunol. 115: 561-566.
60. HAYEM, G., P. NICAISE-ROLAND, E. PALAZZO, et al. 2001. Anti-oxidized low-densitylipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 10: 346-351.
61. ORCHARD, T.J., G. VIRELLA, K.Y. FORREST, et al. 1999. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes. Diabetes 48: 1454-1458.
62. BOUMA, B., P.G. DE GROOT, J.M VAN DEN ELSEN, et al. 1999. Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 18: 5166-5174.
63. HOSHINO, M., Y. HAGIHARA, I. NISHII, et al. 2000. Identification of the phospholipid-binding site of human β2-glycoprotein I domain V by heteronuclear magnetic resonance. J. Mol. Biol. 304: 927-939.
64. INANC, M., E.L. RADWAY-BRIGHT & D.A. ISENBERG. 1997. β2-glycoprotein I and anti-β2-glycoprotein I antibodies: where are we now? Br. J. Rheumatol. 36: 1247-1257.
65. SHENG, Y., D.A. KANDIAH & S.A. KRILIS. 1998. β2-glycoprotein I: target antigen for 'antiphospholipid' antibodies. Immunological and molecular aspects. Lupus 7: S5-9.
66. MERRILL, J.T., H.W. ZHANG, C. SHEN, et al. 1999. Enhancement of protein S anticoagulant function by β2-glycoprotein I, a major target antigen of antiphospholipid antibodies: β2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4β-binding protein. Thromb. Haemost. 81: 748-757.
67. HASHIMOTO, Y., M. KAWAMURA, K. ICHIKAWA, et al. 1992. Anticardiolipin antibodies in NZW × BXSB F1 mice. A model of antiphospholipid syndrome. J. Immunol. 149: 1063-1068.
68. LOPEZ, D., I. GARCIA-VALLADARES, C. PALAFOX-SANCHEZ, et al. 2004. Oxidized low-density lipoprotein/β2-glycoprotein I complexes and autoantibodies to oxLig-1/β2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am. J. Clin. Pathol. 121: 426-436.
69. LOPEZ, D., K. KOBAYASHI, J.T. MERRILL, et al. 2003. IgG Autoantibodies against b2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin. Dev. Immunol. 10: 203-211.